Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. - Wikidata - wikimedia - TriplyDB

Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.

Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.

http://www.wikidata.org/entity/Q48081521

about

Detection of prion protein in urine-derived injectable fertility products by a targeted proteomic approach Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion Vertical transmission of the hepatitis C virus: Current knowledge and issues Estimate of the residual risk of transfusion-transmitted human immunodeficiency virus infection in sub-Saharan Africa: a multinational collaborative study.Clinical review: Fresh frozen plasma in massive bleedings - more questions than answers.Do expert assessments converge? An exploratory case study of evaluating and managing a blood supply risk.Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010.Risk of window period HIV infection in high infectious risk donors: systematic review and meta-analysis Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis.Occult hepatitis B virus infection and blood transfusion Guidance on the use of increased infectious risk donors for organ transplantation.Pre- and post-transfusion testing for hepatitis B virus surface antigen and antibody in blood recipients: a single-institution experience in an area of high endemicity.Reducing the risk of hepatitis B virus transfusion-transmitted infection What every physician should know about transfusion reactions.Blood donors' positivity for transfusion-transmissible infections: the Serbian Military Medical Academy experience.Prevalence, incidence, and residual risks for transfusion-transmitted human immunodeficiency virus Types 1 and 2 infection among Chinese blood donors.Pathogen inactivation: making decisions about new technologies - preliminary report of a consensus conference.Undisclosed human immunodeficiency virus risk factors identified through a computer-based questionnaire program among blood donors in Brazil.Pathogen inactivation: making decisions about new technologies. Report of a consensus conference.CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment Reduction of the risk of bacterial contamination of blood components through diversion of the first part of the donation of blood and blood components Accuracy of physician reporting in routine public health surveillance for hepatitis C virus infection.Assessment and treatment of preoperative anemia: Continuing Professional Development.Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.Two cases of transfusion-transmitted hepatitis B virus (HBV) infection in a low-endemic country before implementation of HBV nucleic acid testing.Human T-lymphotropic virus and transfusion safety: does one size fit all?A comparison of methods for estimating the incidence of human immunodeficiency virus infection in repeat blood donors.Selection strategies for newly registered blood donors in European countries.Evaluation of an isolation program of hepatitis C virus infected hemodialysis patients in some hemodialysis centers in egypt.Estimating window period blood donations for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus by nucleic acid amplification testing in Southern Pakistan.The epidemiology of human T-cell lymphotropic virus types I and II in Canadian blood donors.Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications.Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services.Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.The persistence of hepatitis C virus transmission risk in China despite serologic screening of blood donations.NAT yield for human immunodeficiency and hepatitis C viruses in Brazilian blood donors: preliminary results.Trends in transfusion-transmissible infections among Australian blood donors from 2005 to 2010.Hepatitis B and residual risk of infection in English and Welsh blood donors, 1996 through 2008.Seroprevalence and incidence of transfusion-transmitted infectious diseases among blood donors from regional blood transfusion centres in Burkina Faso, West Africa.

P2860

Q21089975-DE6C9DDF-5B30-482C-A2FB-CEB87DA01B95 Q24200170-5BFC8DCC-6F46-4736-8D32-B1B9CD90F38E Q24234502-3A29CF67-2EDB-4073-89C5-3179A84773C3 Q24652942-89A61416-0F0D-4282-A06E-36477E89790A Q30394281-376050FE-AE53-4687-AFFD-95E1C67BD2B8 Q33873316-1DD96311-3D85-4A49-8C98-0615551C5F7A Q34001785-40ECC256-0BC7-4020-B7AD-B290B99CECFE Q34346207-5FA2CD39-6708-418F-BF52-4E5C4A801F1E Q35032348-E79CB985-99D5-43B9-A22F-C90C49121E2A Q35032861-18A26B49-2936-451D-9149-E5AE6E56B6A8 Q35237335-2D97D9E3-61A2-43E7-AFD9-999D7F0C0DA1 Q35295449-654C194D-746C-49D1-B677-A0622AE7EE81 Q35664869-A3CF1B47-32F4-4E16-AFAA-48CAECC0780E Q35683881-1C33E42C-49ED-4FAE-AA50-C62836A1159E Q35878583-3DE17447-29B7-4635-A8B4-1F3EC250DE23 Q36220045-BEAFD60E-B3AE-4A21-87EF-E094CD181C19 Q36652701-738DD959-6038-4092-8264-818756B4262F Q36903922-3A9B2F3F-7C4C-47B6-A1D6-631EDCB5387B Q37004488-B501401C-A0CD-4E63-8461-970EAE4C6C7A Q37013124-AC9E0AB0-5693-435B-AB27-5021418775AE Q37100669-DD522DD6-02FC-4DDA-BC6F-E6305F4A5815 Q37209101-6ACEC426-6E53-4440-A6EF-09F7F55E6D5F Q37391715-FAFF5967-6159-4E5D-8B31-C583EF386274 Q37864226-31179F65-EB82-41EB-8F18-8D5DD7CC8E24 Q37997349-D85208E6-A63A-4405-937D-C79ED541EF96 Q38403039-E57AB498-C864-4200-AEF9-01BC4665D3FD Q38590004-F2A7DD37-652A-45A1-9C97-DBDC4576286A Q39137413-835F81DC-4B5A-4532-9FBE-379295DAC70C Q39306032-994061FC-3ABB-4AD8-BAC9-B131B82DF6A1 Q40305015-26FDAE4A-61D4-4BA9-B4D4-413386BB0668 Q42245717-EB956D1A-1CA1-4474-85CD-1BC31A8D6399 Q42283514-438340E6-BEA2-4CF7-835D-0AED8C4D35BC Q42588946-6C6190CB-1DB6-4EDD-BA02-791EB957884A Q42977201-46D28AEC-9375-4905-B6FD-91F3A413173A Q42981169-4BD1C123-4269-4CC0-938D-AFFF7361C165 Q42993391-DC2F8CC4-37FD-4CE7-910C-AB3E152BB834 Q43047121-80D6CB6D-94F1-49E3-AD5F-3EA7020E7540 Q43406238-6CB9ACC8-FCB4-4316-926E-6C7C6C6BCDDE Q43851125-37F22279-93DD-4214-B8EA-DFB2945A0C78 Q43870929-FD126C9C-538C-44B9-B81E-5AB6C820C83C

P2860

Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.

http://www.wikidata.org/entity/Q48081521

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Current incidence and estimate ...... de to Canadian Blood Services.

@en

Current incidence and estimate ...... de to Canadian Blood Services.

@nl

type

label

Current incidence and estimate ...... de to Canadian Blood Services.

@en

Current incidence and estimate ...... de to Canadian Blood Services.

@nl

prefLabel

Current incidence and estimate ...... de to Canadian Blood Services.

@en

Current incidence and estimate ...... de to Canadian Blood Services.

@nl

P1433

Q48081521-B30977E0-AC3A-4BC0-9A30-3EA84C84C2AD

P1476

Q48081521-E0E1804E-2ED8-4F2F-A2D2-932A60561A72

P2093

Q48081521-1196648B-4107-4891-8C8B-43F78C921421

Q48081521-958CC303-930B-45F3-A354-A457A97C6535

Q48081521-9AC427F8-9694-4AEF-8078-20BF1E656805

Q48081521-C3D5679A-BAAD-4F72-BA42-BBCD9FF61570

Q48081521-D807F111-9D0D-46E2-A5A4-D0EC684E0FE4

Q48081521-F17CC220-AD5E-441C-B401-C07B1BCE31A0

P2860

Q48081521-00C1B406-0ACA-49FC-B22E-F69DAB1F8D88

Q48081521-0A1E9BC6-0328-42DC-A316-9E6EC914E7F5

Q48081521-1ADA7835-361B-46F7-BA8C-659179838F4F

Q48081521-2D0627A0-3DD0-465D-B6D6-B19704FFB9C1

Q48081521-42756929-2832-4D7E-90C5-454D7EE115DA

Q48081521-4DD9A57B-E1C0-426A-B6C2-6EA34879EF77

Q48081521-5C1C655A-B43B-4542-AABB-5B4214C5F254

Q48081521-676A04D1-D471-48CA-ADC9-EEC696F73C07

Q48081521-67B323BA-F425-450D-AC91-A8A0745888CF

Q48081521-7171D5B5-CBE7-4FCD-AD72-9E1419FD256A

P304

Q48081521-3C760A67-CB33-4354-9242-5D67110AB603

P31

Q48081521-7829019B-9CE0-44D0-802C-7F4803A79BD0

P356

Q48081521-2CBCEB0D-A442-456E-858F-7EC933EC7E39

P433

Q48081521-7ED35A19-7E8B-4690-B04D-C3B70AEF6327

P478

Q48081521-9AF29A26-1853-4580-82A8-0BA7A7E00300

P577

Q48081521-7053C484-DC9E-4639-A0A9-91E4DE2DDDF5

P698

Q48081521-14ECD59E-C90D-457C-BCE3-5D1B239C819E

P356

J.1537-2995.2007.01108.X

P1433

P1476

Current incidence and estimate ...... de to Canadian Blood Services.

@en

P2093

Eleftherios C Vamvakas

http://www.w3.org/2001/XMLSchema#string

Qi-Long Yi

http://www.w3.org/2001/XMLSchema#string

Sheila F O'Brien

http://www.w3.org/2001/XMLSchema#string

Steven H Kleinman

http://www.w3.org/2001/XMLSchema#string

Vito Scalia

http://www.w3.org/2001/XMLSchema#string

Wenli Fan

http://www.w3.org/2001/XMLSchema#string

P2860

Risks associated with transfusion of cellular blood components in Canada.

Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening.

Endpoints in clinical trials on transfusion requirements: the need for a structured approach.

Detection of HCV and HIV-1 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing.

New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.

Assessing the impact of HBV NAT on window period reduction and residual risk.

Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.

Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT.

The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection.

Relevance of RIBA-3 supplementary test to HCV PCR positivity and genotypes for HCV confirmation of blood donors.

P304

316-325

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1537-2995.2007.01108.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17302779

http://www.w3.org/2001/XMLSchema#string